后疫情时代IVF治疗优先级:基于英国国家数据的预测模型研究
该研究基于英国HFEA注册数据中9589名2017年首次接受IVF或ICSI治疗的女性,使用三种预测模型估计推迟6或12个月开始治疗对不同年龄和不同不孕原因女性活产概率的影响。结果显示推迟治疗降低所有夫妇的成功率,但对高龄和已知不孕原因者影响更大,对不明原因不孕者影响较小,部分可自然妊娠。建议疫情后优先安排高龄和已知不孕原因的女性。
要点
- 推迟6个月使各年龄组IVF活产率降低0.4%至11.8%,推迟12个月降低0.9%至22.4%。
- 高龄和已知不孕原因(如输卵管因素、男性因素)女性推迟治疗活产率下降更明显。
- 不明原因不孕女性推迟6个月后活产率反高于立即治疗,因等待期可自然妊娠。
核心结论
- 推迟开始IVF会降低所有夫妇的成功率,但对高龄和已知不孕原因者影响更大,对不明原因不孕者影响较小。
- 疫情后诊所恢复服务时应优先安排高龄女性和已知不孕原因的女性。
研究设计与样本
- 基于英国HFEA注册数据的 population-based 队列研究,纳入9589名2017年首次接受IVF或ICSI治疗并同意数据用于研究的女性。
- 使用三种预测模型估计立即治疗与推迟6或12个月开始治疗的活产概率。
主要发现
- 推迟6个月使活产率降低:<30岁0.4%、30-35岁2.4%、36-37岁5.6%、38-39岁9.5%、40-42岁11.8%。
- 推迟12个月使活产率降低:<30岁0.9%、30-35岁4.9%、36-37岁11.9%、38-39岁18.8%、40-42岁22.4%。
- 输卵管因素不孕女性推迟6个月后一个完整IVF周期的活产率最差(最好)情况:<30岁31.6%(35.0%)、30-35岁29.0%(31.6%)、36-37岁23.1%(25.2%)、38-39岁17.2%(19.4%)、40-42岁10.3%(12.3%)。
- 男性因素不孕女性推迟6个月后活产率最差(最好)情况:<30岁34.3%(39.2%)、30-35岁31.6%(35.3%)、36-37岁25.2%(28.5%)、38-39岁18.3%(21.3%)、40-42岁11.3%(14.1%)。
- 不明原因不孕女性推迟6个月后活产率:<30岁41.0%、30-35岁36.6%、36-37岁29.4%、38-39岁22.4%、40-42岁15.1%,高于立即治疗组的34.9%、32.5%、26.9%、20.7%、13.2%。
关键数值与推荐
- 推迟6个月后一个完整IVF周期的活产率:输卵管因素不孕各年龄组最差31.6%至10.3%,最好35.0%至12.3%;男性因素不孕最差34.3%至11.3%,最好39.2%至14.1%。
- 立即治疗组活产率:输卵管因素不孕31.7%至11.7%,男性因素不孕34.4%至12.8%。
- 不明原因不孕推迟6个月后活产率41.0%至15.1%,立即治疗组34.9%至13.2%。
- 推迟6个月使不明原因不孕女性活产相对数增加:<30岁17.5%、30-35岁12.6%、36-37岁9.1%、38-39岁8.4%、40-42岁13.8%。
临床怎么用
- 疫情后恢复IVF服务时,应优先安排高龄女性和已知不孕原因(如输卵管因素、男性因素)的女性。
- 对不明原因不孕的年轻女性,适当推迟治疗可能不会显著降低活产率,甚至因等待期自然妊娠而增加活产数。
- 临床咨询时应结合年龄和不孕原因个体化评估推迟治疗的風險。
局限性
- 预测模型基于不同人群生成,需多项假设,存在不精确性可能。
- 预测的活产率需前瞻性研究验证准确性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Can we use prediction modelling to estimate the impact of coronavirus disease 2019 (COVID 19) related delay in starting IVF or ICSI in different groups of women? SUMMARY ANSWER: Yes, using a combination of three different models we can predict the impact of delaying access to treatment by 6 and 12 months on the probability of conception leading to live birth in women of different age groups with different categories of infertility. WHAT IS KNOWN ALREADY: Increased age and duration of infertility can prejudice the chances of success following IVF, but couples with unexplained infertility have a chance of conceiving naturally without treatment whilst waiting for IVF. The worldwide suspension of IVF could lead to worse outcomes in couples awaiting treatment, but it is unclear to what extent this could affect individual couples based on age and cause of infertility. STUDY DESIGN, SIZE, DURATION: A population-based cohort study based on national data from all licensed clinics in the UK obtained from the Human Fertilisation and Embryology Authority Register. Linked data from 9589 women who underwent their first IVF or ICSI treatment in 2017 and consented to the use of their data for research were used to predict livebirth. PARTICIPANTS/MATERIALS, SETTING, METHODS: Three prediction models were used to estimate the chances of livebirth associated with immediate treatment versus a delay of 6 and 12 months in couples about to embark on IVF or ICSI. MAIN RESULTS AND THE ROLE OF CHANCE: We estimated that a 6-month delay would reduce IVF livebirths by 0.4%, 2.4%, 5.6%, 9.5% and 11.8% in women aged <30, 30-35, 36-37, 38-39 and 40-42 years, respectively, while corresponding values associated with a delay of 12 months were 0.9%, 4.9%, 11.9%, 18.8% and 22.4%, respectively. In women with known causes of infertility, worst case (best case) predicted chances of livebirth after a delay of 6 months followed by one complete IVF cycle in women aged <30, 30-35, 36-37, 38-39 and 40-42 years varied between 31.6% (35.0%), 29.0% (31.6%), 23.1% (25.2%), 17.2% (19.4%) and 10.3% (12.3%) for tubal infertility and 34.3% (39.2%), 31.6% (35.3%) 25.2% (28.5%) 18.3% (21.3%) and 11.3% (14.1%) for male factor infertility. The corresponding values in those treated immediately were 31.7%, 29.8%, 24.5%, 19.0% and 11.7% for tubal factor and 34.4%, 32.4%, 26.7%, 20.2% and 12.8% in male factor infertility. In women with unexplained infertility the predicted chances of livebirth after a delay of 6 months followed by one complete IVF cycle were 41.0%, 36.6%, 29.4%, 22.4% and 15.1% in women aged <30, 30-35, 36-37, 38-39 and 40-42 years, respectively, compared to 34.9%, 32.5%, 26.9%, 20.7% and 13.2% in similar groups of women treated without any delay. The additional waiting period, which provided more time for spontaneous conception, was predicted to increase the relative number of babies born by 17.5%, 12.6%, 9.1%, 8.4% and 13.8%, in women aged <30, 30-35, 36-37, 38-39 and 40-42 years, respectively. A 12-month delay showed a similar pattern in all subgroups. LIMITATIONS, REASONS FOR CAUTION: Major sources of uncertainty include the use of prediction models generated in different populations and the need for a number of assumptions. Although the models are validated and the bases for the assumptions are robust, it is impossible to eliminate the possibility of imprecision in our predictions. Therefore, our predicted live birth rates need to be validated in prospective studies to confirm their accuracy. WIDER IMPLICATIONS OF THE FINDINGS: A delay in starting IVF reduces success rates in all couples. For the first time, we have shown that while this results in fewer babies in older women and those with a known cause of infertility, it has a less detrimental effect on couples with unexplained infertility, some of whom conceive naturally whilst waiting for treatment. Post-COVID 19, clinics planning a phased return to normal clinical services should prioritize older women and those with a known cause of infertility. STUDY FUNDING/COMPETING INTEREST(S): No external funding was received for this study. B.W.M. is supported by an NHMRC Practitioner Fellowship (GNT1082548) and reports consultancy work for ObsEva, Merck, Merck KGaA, Guerbet and iGenomics. S.B. is Editor-in-Chief of Human Reproduction Open. None of the other authors declare any conflicts of interest. TRIAL REGISTRATION NUMBER: N/A.
引用
- Bhattacharya S, Maheshwari A, Ratna MB, et al. Prioritizing IVF treatment in the post-COVID 19 era: a predictive modelling study based on UK national data. Hum Reprod. 2021. PMID: 33226080. doi:10.1093/humrep/deaa339
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。